We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Lung Cancer Test Predicts Survival in Early Stages Better Than Current Methods

By LabMedica International staff writers
Posted on 14 Jan 2025

Biological markers in lung cancer can help doctors identify patients who are at higher risk of their cancer returning or spreading to other parts of the body. More...

This is especially important for individuals with stage 1 lung cancer, who typically undergo surgery without chemotherapy. However, for about 25% of stage 1 patients, the cancer returns, suggesting that they may have benefited from more frequent monitoring or chemotherapy. When doctors take a tumor sample, they generally only capture less than 1% of the tumor, and the genetic makeup can vary greatly from one region of the tumor to another. In 2019, a test called ORACLE was developed to address the lack of biological markers in lung cancer by analyzing genes that are expressed at high or low levels throughout the entire tumor. Researchers have now shown that ORACLE can predict lung cancer survival at the time of diagnosis more effectively than the clinical risk factors currently in use. This could help doctors make better-informed treatment decisions for stage 1 lung cancer patients, potentially reducing the likelihood of cancer recurrence or spread.

In a collaborative study involving researchers from the Francis Crick Institute (London, UK), the team tested ORACLE in 158 individuals with lung cancer as part of the Cancer Research UK-funded TRACERx study. The results indicated that ORACLE could predict patient survival more accurately than the current clinical standards, such as tumor stage. These new findings suggest that ORACLE could identify stage 1 lung cancer patients with a lower chance of survival who might benefit from chemotherapy in addition to surgery. Current clinical standards were not able to provide this information for stage 1 patients. Published in the journal Nature Cancer, the research also showed that high ORACLE risk scores were associated with regions of the tumor that were more likely to metastasize.

Moreover, when the researchers examined 359 current and potential lung cancer drugs, they found that high ORACLE risk scores predicted a better response to certain types of chemotherapy, particularly platinum-based drugs like cisplatin. This is because regions of the tumor with high ORACLE scores tend to have unstable DNA, known as chromosomal instability, which is specifically targeted by platinum drugs. The same research team recently discovered that alterations in a key gene called FAT1 contribute to chromosomal instability, and FAT1 is also one of the genetic variations that ORACLE detects. Moving forward, the researchers plan to compare outcomes for individuals with high ORACLE scores receiving standard care versus those receiving additional surveillance or chemotherapy, to determine if the test improves survival, even for those diagnosed at the earliest stage.

“ORACLE can now predict survival rates in patients diagnosed at the earliest stage,” said Dhruva Biswas, Translation Fellow at the Crick, Postdoctoral Fellow at the UCL Cancer Institute, Associate Research Scientist at Yale School of Medicine, and co-first author. “If validated in larger cohorts of patients with lung cancer, doctors could one day use ORACLE to help make informed treatment decisions, bringing lessons from cancer evolution into the clinic.”

Related Links:
Francis Crick Institute


Gold Member
Troponin T QC
Troponin T Quality Control
Serological Pipet Controller
PIPETBOY GENIUS
New
Multilevel Whole Blood Calibrator Set
6PLUS1
New
cDNA Synthesis Kit
Ultimate cDNA Synthesis Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Ear wax could be a possible screening medium for Parkinson’s disease (Photo courtesy of 123RF)

Earwax Test Accurately Detects Parkinson’s by Identifying Odor Molecules

Current tests for Parkinson’s disease (PD) rely heavily on clinical scales and neuroimaging, which are often subjective, expensive, and ill-suited for routine screening. Since most treatments only slow... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: NGS can detect one tumor cell among a million healthy cells from a simple blood sample (Photo courtesy of Shutterstock)

New Tool Detects Breast Cancer Relapses Five Years in Advance

Relapse detection in patients with solid tumors—particularly hormone receptor-positive (HR+) breast cancer—remains a major clinical challenge, as many patients initially respond well to treatment but later... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.